PL2619208T3 - Związki imidazotriazynonu - Google Patents
Związki imidazotriazynonuInfo
- Publication number
- PL2619208T3 PL2619208T3 PL11761793T PL11761793T PL2619208T3 PL 2619208 T3 PL2619208 T3 PL 2619208T3 PL 11761793 T PL11761793 T PL 11761793T PL 11761793 T PL11761793 T PL 11761793T PL 2619208 T3 PL2619208 T3 PL 2619208T3
- Authority
- PL
- Poland
- Prior art keywords
- imidazotriazinone compounds
- imidazotriazinone
- compounds
- Prior art date
Links
- IJYHVZICHKCLMQ-UHFFFAOYSA-N imidazo[4,5-d]triazin-4-one Chemical class O=C1N=NN=C2N=CN=C12 IJYHVZICHKCLMQ-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Anesthesiology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38469410P | 2010-09-20 | 2010-09-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2619208T3 true PL2619208T3 (pl) | 2017-03-31 |
Family
ID=44720178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11761793T PL2619208T3 (pl) | 2010-09-20 | 2011-09-20 | Związki imidazotriazynonu |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20120157458A1 (enExample) |
| EP (2) | EP3181566A1 (enExample) |
| JP (2) | JP5855109B2 (enExample) |
| CN (1) | CN103313988B (enExample) |
| AR (1) | AR083058A1 (enExample) |
| AU (2) | AU2011305568B2 (enExample) |
| BR (1) | BR112013008140A8 (enExample) |
| CA (1) | CA2811714C (enExample) |
| DK (1) | DK2619208T3 (enExample) |
| ES (1) | ES2610360T3 (enExample) |
| MX (1) | MX2013003093A (enExample) |
| PL (1) | PL2619208T3 (enExample) |
| RU (1) | RU2603140C2 (enExample) |
| TW (1) | TWI541244B (enExample) |
| UY (1) | UY33616A (enExample) |
| WO (1) | WO2012040230A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2619208T3 (pl) * | 2010-09-20 | 2017-03-31 | Ironwood Pharmaceuticals, Inc. | Związki imidazotriazynonu |
| HK1211023A1 (zh) * | 2011-10-10 | 2016-05-13 | H. Lundbeck A/S | 具有咪唑并吡嗪骨架pde9i |
| EP3178820B1 (en) | 2012-01-26 | 2017-12-20 | H. Lundbeck A/S | Pde9- inhibitors with imidazo triazinone backbone |
| HK1206726A1 (en) | 2012-03-19 | 2016-01-15 | Ironwood Pharmaceuticals, Inc. | Imidazotriazinone compounds |
| CN102786525B (zh) | 2012-08-08 | 2014-12-17 | 中山大学 | N-取代吡唑并[3,4-d]嘧啶酮类化合物、其制备方法及其应用 |
| WO2014024125A1 (en) | 2012-08-08 | 2014-02-13 | Celon Pharma S.A. | Pyrazolo[4,3-d]pyrimidin-7(6h)-one derivatives as pde9 inhibitors |
| JP2016503395A (ja) | 2012-10-31 | 2016-02-04 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | 病害生物防除剤としての複素環化合物 |
| TW201629064A (zh) | 2014-10-10 | 2016-08-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之三唑並吡酮 |
| WO2016147659A1 (en) * | 2015-03-16 | 2016-09-22 | Sumitomo Dainippon Pharma Co., Ltd. | Bicyclic imidazolo derivative |
| TW201643167A (zh) * | 2015-04-22 | 2016-12-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之咪唑並三酮 |
| JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
| AU2016289856B2 (en) | 2015-07-07 | 2020-11-26 | H. Lundbeck A/S | PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases |
| WO2017070293A1 (en) * | 2015-10-20 | 2017-04-27 | Ironwood Pharmaceuticals, Inc. | Phosphodiesterase 9 inhibitor and levodopa therapy |
| CN105669680B (zh) * | 2016-03-24 | 2018-02-23 | 南京药捷安康生物科技有限公司 | 吡咯并[2,1‑f][1,2,4]三嗪‑4(1H)‑酮衍生物类PDE9A抑制剂 |
| TWI729109B (zh) | 2016-04-12 | 2021-06-01 | 丹麥商Ｈ 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
| TN2018000383A1 (en) | 2016-07-06 | 2020-06-15 | H Lundbeck As | Pde9 inhibitors for treatment of peripheral diseases. |
| EP3529250B1 (en) | 2016-10-18 | 2023-12-06 | H. Lundbeck A/S | Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as pde1 inhibitors |
| JP2019536762A (ja) | 2016-10-28 | 2019-12-19 | ハー・ルンドベック・アクチエゼルスカベット | 精神疾患及び／又は認知障害の治療のためのイミダゾピラジノンを含む併用療法 |
| KR20190077349A (ko) | 2016-10-28 | 2019-07-03 | 하. 룬드벡 아크티에셀스카브 | 이미다조피라지논의 투여를 포함하는 병용 치료 |
| CN115746003B (zh) * | 2017-05-26 | 2024-08-09 | 卡都瑞恩医药公司 | 制备和使用pde9抑制剂的方法 |
| ES2975792T3 (es) | 2018-05-25 | 2024-07-15 | Cardurion Pharmaceuticals Inc | Monohidrato y formas cristalinas de 6-[(3s,4s)-4-metil-1- (pirimidin-2-ilmetil)pirrolidin-3-il]-3-tetrahidropiran-4-il-7H-imidazo[1,5-a]pirazin-8-ona |
| KR20250108770A (ko) | 2018-08-31 | 2025-07-15 | 카듀리온 파마슈티칼스, 인크. | 겸상 세포 질환의 치료를 위한 pde9 억제제 |
| WO2020102374A1 (en) * | 2018-11-14 | 2020-05-22 | The Board Of Trustees Of The Leland Stanford Junior University | Targeting of makap-pde4d3 complexes in neurodegenerative disease |
| KR102712818B1 (ko) * | 2018-12-06 | 2024-09-30 | 한국화학연구원 | Pde9a 저해 활성을 가지는 화합물 및 이들의 의약 용도 |
| CN114929231B (zh) * | 2019-10-21 | 2024-11-29 | 爱思开生物制药株式会社 | 咪唑并嘧啶或咪唑并三嗪化合物用于预防、减轻或治疗发育性残疾的用途 |
| CN112724079A (zh) * | 2021-02-04 | 2021-04-30 | 康化（上海）新药研发有限公司 | 一种6-甲氧基吡啶甲酸甲酯的合成方法 |
| GB2632307A (en) * | 2023-08-02 | 2025-02-05 | Duke Street Bio Ltd | PARP1 inhibitor compounds |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
| DE19750085A1 (de) * | 1997-11-12 | 1999-05-20 | Bayer Ag | 2-Phenyl-substituierte Imidazotriazinone |
| SK287161B6 (sk) | 1997-11-12 | 2010-02-08 | Bayer Healthcare Ag | 2-Fenylsubstituované imidazotriazinóny, spôsob ich výroby, liečivá obsahujúce tieto látky a ich použitie |
| US7087605B2 (en) | 2001-06-01 | 2006-08-08 | Bayer Aktiengesellschaft | 5-Ethyl-imidazotriazinones |
| GB0113343D0 (en) * | 2001-06-01 | 2001-07-25 | Bayer Ag | Novel Heterocycles 2 |
| CA2465632A1 (en) * | 2001-11-02 | 2003-05-08 | Pfizer Products Inc. | Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| DE10229778A1 (de) * | 2002-07-03 | 2004-01-29 | Bayer Ag | Neue Verwendung von Imidazotriazinonen |
| US20040220186A1 (en) * | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
| US20060264624A1 (en) | 2005-05-20 | 2006-11-23 | Alexander Heim-Riether | Methods for synthesizing imidazotriazinones |
| JP2008543968A (ja) | 2005-06-28 | 2008-12-04 | オーキッド リサーチ ラボラトリーズ リミテッド | 新規なピラゾロピリミジノン誘導体 |
| HRP20120105T1 (hr) * | 2007-05-11 | 2012-02-29 | Pfizer Inc. | Aminoheterociklički spojevi |
| CN102131801B (zh) | 2008-06-25 | 2015-04-08 | 福拉姆医药股份有限公司 | 1,2-二取代的杂环化合物 |
| PL2619208T3 (pl) | 2010-09-20 | 2017-03-31 | Ironwood Pharmaceuticals, Inc. | Związki imidazotriazynonu |
| EP3178820B1 (en) | 2012-01-26 | 2017-12-20 | H. Lundbeck A/S | Pde9- inhibitors with imidazo triazinone backbone |
| HK1206726A1 (en) | 2012-03-19 | 2016-01-15 | Ironwood Pharmaceuticals, Inc. | Imidazotriazinone compounds |
-
2011
- 2011-09-20 PL PL11761793T patent/PL2619208T3/pl unknown
- 2011-09-20 RU RU2013118362/04A patent/RU2603140C2/ru not_active IP Right Cessation
- 2011-09-20 BR BR112013008140A patent/BR112013008140A8/pt not_active IP Right Cessation
- 2011-09-20 CN CN201180055157.9A patent/CN103313988B/zh not_active Expired - Fee Related
- 2011-09-20 TW TW100133825A patent/TWI541244B/zh not_active IP Right Cessation
- 2011-09-20 CA CA2811714A patent/CA2811714C/en not_active Expired - Fee Related
- 2011-09-20 EP EP16197573.5A patent/EP3181566A1/en not_active Withdrawn
- 2011-09-20 MX MX2013003093A patent/MX2013003093A/es active IP Right Grant
- 2011-09-20 UY UY0001033616A patent/UY33616A/es unknown
- 2011-09-20 AU AU2011305568A patent/AU2011305568B2/en not_active Ceased
- 2011-09-20 EP EP11761793.6A patent/EP2619208B1/en not_active Not-in-force
- 2011-09-20 US US13/237,795 patent/US20120157458A1/en not_active Abandoned
- 2011-09-20 WO PCT/US2011/052399 patent/WO2012040230A1/en not_active Ceased
- 2011-09-20 ES ES11761793.6T patent/ES2610360T3/es active Active
- 2011-09-20 DK DK11761793.6T patent/DK2619208T3/en active
- 2011-09-20 AR ARP110103426A patent/AR083058A1/es unknown
- 2011-09-20 JP JP2013530234A patent/JP5855109B2/ja not_active Expired - Fee Related
-
2014
- 2014-07-17 US US14/334,073 patent/US9540380B2/en not_active Expired - Fee Related
-
2015
- 2015-12-08 JP JP2015239514A patent/JP2016104747A/ja active Pending
-
2016
- 2016-02-16 AU AU2016200970A patent/AU2016200970A1/en not_active Abandoned
- 2016-12-07 US US15/371,935 patent/US20170152265A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012040230A1 (en) | 2012-03-29 |
| RU2013118362A (ru) | 2014-10-27 |
| BR112013008140A2 (pt) | 2017-12-05 |
| TW201217381A (en) | 2012-05-01 |
| EP3181566A1 (en) | 2017-06-21 |
| US20170152265A1 (en) | 2017-06-01 |
| HK1187908A1 (en) | 2014-04-17 |
| JP5855109B2 (ja) | 2016-02-09 |
| RU2603140C2 (ru) | 2016-11-20 |
| BR112013008140A8 (pt) | 2018-04-03 |
| AU2011305568B2 (en) | 2015-12-10 |
| AR083058A1 (es) | 2013-01-30 |
| EP2619208A1 (en) | 2013-07-31 |
| CA2811714C (en) | 2017-11-21 |
| AU2011305568A1 (en) | 2013-04-04 |
| CN103313988A (zh) | 2013-09-18 |
| US20140330014A1 (en) | 2014-11-06 |
| CA2811714A1 (en) | 2012-03-29 |
| JP2016104747A (ja) | 2016-06-09 |
| US20120157458A1 (en) | 2012-06-21 |
| CN103313988B (zh) | 2016-06-08 |
| JP2013540755A (ja) | 2013-11-07 |
| MX2013003093A (es) | 2013-10-28 |
| DK2619208T3 (en) | 2017-01-30 |
| ES2610360T3 (es) | 2017-04-27 |
| AU2016200970A1 (en) | 2016-03-03 |
| TWI541244B (zh) | 2016-07-11 |
| US9540380B2 (en) | 2017-01-10 |
| UY33616A (es) | 2012-04-30 |
| EP2619208B1 (en) | 2016-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL223783A0 (en) | Pro-neurogenic compounds | |
| GB201008134D0 (en) | Compounds | |
| GB201015949D0 (en) | Compounds | |
| GB201007286D0 (en) | New compounds | |
| GB201020179D0 (en) | New compounds | |
| AP2012006641A0 (en) | New compounds | |
| PL2619208T3 (pl) | Związki imidazotriazynonu | |
| PL2648516T3 (pl) | Podstawione związki pirydynono-pirydynylowe | |
| GB201007347D0 (en) | Compounds | |
| EP2649050A4 (en) | LINKS | |
| GB201002563D0 (en) | Compounds | |
| GB201008209D0 (en) | Compounds | |
| GB201001688D0 (en) | Compounds | |
| GB201002216D0 (en) | Compounds | |
| GB201001796D0 (en) | Compounds | |
| GB201015537D0 (en) | Compounds | |
| GB201008210D0 (en) | Compounds | |
| GB201021494D0 (en) | Compounds | |
| GB201013507D0 (en) | Compounds | |
| GB201014052D0 (en) | Compounds | |
| GB201015145D0 (en) | Compounds | |
| GB201002708D0 (en) | Compounds | |
| GB201005727D0 (en) | Compounds | |
| GB201005821D0 (en) | Immunomoduatory compounds | |
| GB201006216D0 (en) | Compounds |